Menu
Back to User profile » Dr Paolo Bonfanti
Papers published by Dr Paolo Bonfanti:
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
Bagella P, Squillace N, Ricci E, Gulminetti R, De Socio GV, Taramasso L, Pellicanò G, Menzaghi B, Celesia BM, Dentone C, Orofino G, Bonfanti P, Madeddu G
Infection and Drug Resistance 2019, 12:1385-1391
Published Date: 23 May 2019
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
Bagella P, De Socio GVL, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G
Infection and Drug Resistance 2018, 11:615-623
Published Date: 26 April 2018
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D
Therapeutics and Clinical Risk Management 2017, 13:787-797
Published Date: 29 June 2017